Abbott Laboratories (ABT) Non-Current Assets (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Non-Current Assets data on file, last reported at $84.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 45.67% year-over-year to $84.9 billion; the trailing twelve-month figure through Mar 2026 stood at $264.5 billion (up 22.17% YoY), and the FY2025 full-year result was $60.7 billion, up 5.12% from the prior year.
• Non-Current Assets rose to $84.9 billion in Q1 2026, from $60.7 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $84.9 billion in Q1 2026 to a low of -$17.2 billion in Q4 2022.
• A 5-year average of $50.6 billion and a median of $50.5 billion in 2023 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets fell 4.67% in 2022 and jumped 393.2% in 2023, its largest moves.
• Tracing ABT's Non-Current Assets over 5 years: stood at -$17.2 billion in 2022, then jumped by 393.2% to $50.5 billion in 2023, then gained by 14.27% to $57.8 billion in 2024, then climbed by 5.12% to $60.7 billion in 2025, then surged by 39.86% to $84.9 billion in 2026.
• Business Quant data shows ABT's Non-Current Assets at $84.9 billion in Q1 2026, $60.7 billion in Q4 2025, and $59.3 billion in Q3 2025.